Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study.

ABSTRACT:

Background

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown cardiovascular benefits in cardiovascular outcome trials in type 2 diabetes mellitus. However, the most convincing evidence was obtained in subjects with established cardiovascular (CV) disease. We analyzed the determinants of GLP-1 RA-mediated CV protection in a real-world population of persons with type 2 diabetes with and without a history of CV events with long-term follow-up.

Methods

Retrospective cohort study of 550 individuals with type 2 diabetes (395 in primary CV prevention, 155 in secondary CV prevention), followed at a single center after the first prescription of a GLP-1 RA between 2009 and 2019. CV and metabolic outcomes were assessed.

Results

Median duration of follow-up was 5.0

SUBMITTER: Piccini S 

PROVIDER: S-EPMC10039680 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature